|
1
|
Rini BI, Campbell SC and Escudier B: Renal
cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
King SC, Pollack LA, Li J, King JB and
Master VA: Continued increase in incidence of renal cell carcinoma,
especially in young patients and high grade disease: United States
2001 to 2010. J Urol. 191:1665–1670. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Linehan WM and Ricketts CJ: Decade in
review-kidney cancer: Discoveries, therapies and opportunities. Nat
Rev Urol. 11:614–616. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bedke J, Gauler T, Grünwald V, Hegele A,
Herrmann E, Hinz S, Janssen J, Schmitz S, Schostak M, Tesch H, et
al: Systemic therapy in metastatic renal cell carcinoma. World J
Urol. 35:179–188. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brown C: Targeted therapy: An elusive
cancer target. Nature. 537 (Suppl):S106–S108. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang F, Wu Q, Zhang Y, Xiong H, Li X, Li
B, Xie W, Zhang L, Xu M, Zhang K and He F: LncRNA LOC653786
promotes growth of RCC cells via upregulating FOXM1. Oncotarget.
9:12101–12111. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choueiri TK and Motzer RJ: Systemic
therapy for metastatic renal-cell carcinoma. N Engl J Med.
376:354–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Al-Hajj M and Clarke MF: Self-renewal and
solid tumor stem cells. Oncogene. 23:7274–7282. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Corrò C and Moch H: Biomarker discovery
for renal cancer stem cells. J Pathol Clin Res. 4:3–18. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L, Wang Q, Mao J, Qin T, Sun Y, Yang
J, Han Y, Li L and Li Q: Salinomycin suppresses cancer cell
stemness and attenuates TGF-β-induced epithelial-mesenchymal
transition of renal cell carcinoma cells. Chem Biol Interact.
296:145–153. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Matak D, Brodaczewska KK, Szczylik C, Koch
I, Myszczyszyn A, Lipiec M, Lewicki S, Szymanski L, Zdanowski R and
Czarnecka AM: Functional significance of CD105-positive cells in
papillary renal cell carcinoma. BMC Cancer. 17:212017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saeednejad Zanjani L, Madjd Z, Abolhasani
M, Shariftabrizi A, Rasti A and Asgari M: Expression of CD105
cancer stem cell marker in three subtypes of renal cell carcinoma.
Cancer Biomark. 21:821–837. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duff SE, Li C, Garland JM and Kumar S:
CD105 is important for angiogenesis: Evidence and potential
applications. FASEB J. 17:984–992. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dallas NA, Samuel S, Xia L, Fan F, Gray
MJ, Lim SJ and Ellis LM: Endoglin (CD105): A marker of tumor
vasculature and potential target for therapy. Clin Cancer Res.
14:1931–1937. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bussolati B, Bruno S, Grange C, Ferrando U
and Camussi G: Identification of a tumor-initiating stem cell
population in human renal carcinomas. FASEB J. 22:3696–3705. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hasmim M, Bruno S, Azzi S, Gallerne C,
Michel JG, Chiabotto G, Lecoz V, Romei C, Spaggiari GM, Pezzolo A,
et al: Isolation and characterization of renal cancer stem cells
from patient-derived xenografts. Oncotarget. 7:15507–15524. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Song L, Ye W, Cui Y, Lu J, Zhang Y, Ding
N, Hu W, Pei H, Yue Z and Zhou G: Ecto-5′-nucleotidase (CD73) is a
biomarker for clear cell renal carcinoma stem-like cells.
Oncotarget. 8:31977–31992. 2017.PubMed/NCBI
|
|
19
|
Feldman DR and Motzer RJ: Novel targets
and therapies for metastatic renal cell carcinoma. Oncology
(Williston Park). 20:1745–1756. 2006.PubMed/NCBI
|
|
20
|
Yang X, Zhang D, Chong T, Li Y, Wang Z and
Zhang P: Expression of CK19, CD105 and CD146 are associated with
early metastasis in patients with renal cell carcinoma. Oncol Lett.
15:4229–4234. 2018.PubMed/NCBI
|
|
21
|
Yagasaki H, Kawata N, Takimoto Y and
Nemoto N: Histopathological analysis of angiogenic factors in renal
cell carcinoma. Int J Urol. 10:220–227. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Saroufim A, Messai Y, Hasmim M, Rioux N,
Iacovelli R, Verhoest G, Bensalah K, Patard JJ, Albiges L, Azzarone
B, et al: Tumoral CD105 is a novel independent prognostic marker
for prognosis in clear-cell renal cell carcinoma. Br J Cancer.
110:1778–1784. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Myszczyszyn A, Czarnecka AM, Matak D,
Szymanski L, Lian F, Kornakiewicz A, Bartnik E, Kukwa W, Kieda C
and Szczylik C: The role of hypoxia and cancer stem cells in renal
cell carcinoma pathogenesis. Stem Cell Rev. 11:919–943. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu J, Guan W, Liu P, Dai J, Tang K, Xiao
H, Qian Y, Sharrow AC, Ye Z, Wu L and Xu H: Endoglin is essential
for the maintenance of self-renewal and chemoresistance in renal
cancer stem cells. Stem Cell Reports. 9:464–477. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Seon BK, Matsuno F, Haruta Y, Kondo M and
Barcos M: Long-lasting complete inhibition of human solid tumors in
SCID mice by targeting endothelial cells of tumor vasculature with
antihuman endoglin immunotoxin. Clin Cancer Res. 3:1031–1044.
1997.PubMed/NCBI
|
